摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

(1S,7aS)-(+)-1-hydroxy-4,7a-dimethyl-2,3,7,7a-tetrahydro-1H-indene-5(6)-one | 212953-00-9

中文名称
——
中文别名
——
英文名称
(1S,7aS)-(+)-1-hydroxy-4,7a-dimethyl-2,3,7,7a-tetrahydro-1H-indene-5(6)-one
英文别名
(+)-(1S,7aS)-1-hydroxy-4,7a-dimethyl-1,2,3,6,7,7a-hexahydro-inden-5-one;2,6β-Dimethyl-3-oxo-bicyclo[4.3.0]non-1-en-7-β-ol;(1S,7AS)-1-Hydroxy-4,7A-dimethyl-1,2,3,6,7,7A-hexahydro-5H-inden-5-one;(1S,7aS)-1-hydroxy-4,7a-dimethyl-2,3,6,7-tetrahydro-1H-inden-5-one
(1S,7aS)-(+)-1-hydroxy-4,7a-dimethyl-2,3,7,7a-tetrahydro-1H-indene-5(6)-one化学式
CAS
212953-00-9
化学式
C11H16O2
mdl
——
分子量
180.247
InChiKey
WNSQFNUOPLRWNQ-QWRGUYRKSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    313.3±31.0 °C(Predicted)
  • 密度:
    1.11±0.1 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    0.9
  • 重原子数:
    13
  • 可旋转键数:
    0
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.73
  • 拓扑面积:
    37.3
  • 氢给体数:
    1
  • 氢受体数:
    2

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

点击查看最新优质反应信息

文献信息

  • Total synthesis of (+)-cyclomyltaylan-5α-ol isolated from the taiwanese liverwort Reboulia hemisphaerica
    作者:Hitoshi Sakai、Hisahiro Hagiwara、Yoshiaki Ito、Takashi Hoshi、Toshio Suzuki、Masayoshi Ando
    DOI:10.1016/s0040-4039(99)00338-x
    日期:1999.4
    The novel tetracyclic sesquiterpenoid (+)-cyclomyltaylan-5α-ol 1 has been synthesized starting from (S)-(+)-Hajos-Wiechert ketone analogue 3via SmI2-promoted reductive cyclization as a key step. Thus, the absolute configuration has been established to be 2R,3R, 4R,5S,6R,7R (cyclomyltaylane numbering) as depicted in structure 1.
    新颖的四环倍半萜(+) - cyclomyltaylan-5α醇1已经合成从(起始小号) - (+) -豪约什-维谢尔酮类似物3经由SMI 2促进的还原性环化作为关键步骤。因此,如结构1中所示,绝对构型已经确定为2 R,3 R,4 R,5 S,6 R,7 R(环戊烷编号)。
  • The first enantioselective total synthesis of cyclomyltaylane-5α-ol and determination of its absolute stereochemistry
    作者:Hisahiro Hagiwara、Hitoshi Sakai、Takashi Uchiyama、Yoshiaki Ito、Noriyuki Morita、Takashi Hoshi、Toshio Suzuki、Masayoshi Ando
    DOI:10.1039/b111594b
    日期:2002.2.22
    (+)-cyclomyltaylan-5α-ol 1 has been synthesized starting from (S)-(+)-Hajos–Wiechert ketone analogue 10via stereoselective Claisen rearrangement followed by SmI2-promoted reductive cyclisation. Thus, the absolute configuration has been established to be 2R,3R,4R,5S,6R,7R (cyclomyltaylane numbering) as depicted in structure 1.
    四环倍半萜(+) - cyclomyltaylan-5α醇1已经合成从(起始小号) - (+) -豪约什-维谢尔酮通过立体声选择的模拟10克莱森重排其次是SmI 2促进的还原环化。因此,如结构1中所示,绝对构型已经确定为2 R,3 R,4 R,5 S,6 R,7 R(环甲亚甲基编号)。
  • Efficient kinetic resolution of (±)-4-methyl-Hajos–Parrish ketone by baker’s yeast reduction
    作者:Hideaki Hioki、Takefumi Hashimoto、Mitsuaki Kodama
    DOI:10.1016/s0957-4166(00)00010-0
    日期:2000.2
    Kinetic resolution of (±)-4-methyl-Hajos–Parrish ketone (±)-2a using baker’s yeast reduction was investigated. The reaction rate and enantiomeric purity depended on the concentration of substrate and yeast. Under concentrated conditions, (−)-2a and the alcohol (+)-3 were obtained in high enantiomeric excess.
    (±)-4-甲基-豪约什-帕里什酮(±)动力学拆分-图2a使用面包酵母还原进行了研究。反应速率和对映体纯度取决于底物和酵母的浓度。在浓缩条件下,以高对映体过量获得(-)- 2a和醇(+)- 3。
  • Novel and general entry into pseudoguaianolides. Formal and enantioselective synthesis of (+)-confertin
    作者:Masafumi Ohtsuka、Yuki Takekawa、Kozo Shishido
    DOI:10.1016/s0040-4039(98)01180-0
    日期:1998.8
    A novel and general access to pseudoguaianolide sesquiterpenoids has been developed by employing a diastereoselective acyl radical-mediated 7-endo-trigonal mode of cyclization as a key reaction step. The methodology has successfully been applied to the formal enantioselective synthesis of (+)-confertin. (C) 1998 Elsevier Science Ltd. All rights reserved.
  • PYRAZOLYL AND PYRIMIDINYL TRICYCLIC ENONES AS ANTIOXIDANT INFLAMMATION MODULATORS
    申请人:Anderson Eric
    公开号:US20120196880A1
    公开(公告)日:2012-08-02
    Disclosed herein are novel antioxidant inflammation modulators, including those of the formula: wherein the variables are defined herein. Also provided are pharmaceutical compositions, kits and articles of manufacture comprising such compounds. Methods and intermediates useful for making the compounds, and methods of using the compounds and compositions thereof are also provided.
查看更多